NCT01987739View on ClinicalTrials.gov

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Abuse Potential Study
Interventions
DRUG

200 mg almorexant

DRUG

400 mg almorexant

DRUG

1000 mg almorexant

DRUG

20 mg zolpidem

DRUG

40 mg zolpidem

DRUG

placebo

Sponsors
All Listed Sponsors
lead

Midnight Pharma, LLC

INDUSTRY